Immune-related Adverse Event Clinical Trials

10 recruiting

Immune-related Adverse Event Trials at a Glance

12 actively recruiting trials for immune-related adverse event are listed on ClinicalTrialsFinder across 6 cities in 6 countries. The largest study group is Not Applicable with 4 trials, with the heaviest enrollment activity in Brisbane, Calgary, and Edmonton. Lead sponsors running immune-related adverse event studies include AHS Cancer Control Alberta, Institut Mutualiste Montsouris, and Centre Hospitalier Universitaire, Amiens.

Browse immune-related adverse event trials by phase

Treatments under study

About Immune-related Adverse Event Clinical Trials

Looking for clinical trials for Immune-related Adverse Event? There are currently 10 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Immune-related Adverse Event trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Immune-related Adverse Event clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 112 of 12 trials

Recruiting
Phase 2

Inhaled Budesonide for REcurrence Prevention and Adjuvant THerapy in Checkpoint Inhibitor Pneumonitis

PneumonitisImmune-related Adverse Event
AHS Cancer Control Alberta94 enrolled1 locationNCT06860542
Recruiting
Phase 2

Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis

Immune-related Adverse EventInflammatory Arthritis
Tom Appleton30 enrolled1 locationNCT06037811
Recruiting
Not Applicable

Adebrelimab Combined With Chemotherapy for the Esophageal Squamous Cell Carcinoma

Quality of LifeObjective Response RatePathological Complete Remission+1 more
The Second Hospital of Shandong University25 enrolled1 locationNCT07430579
Recruiting
Phase 2

Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo)

Advanced MelanomaDiarrheaImmune-related Adverse Event+1 more
AHS Cancer Control Alberta20 enrolled1 locationNCT05663775
Recruiting
Not Applicable

Identification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients Undergoing Immune CheckPoint Inhibitors (ICPI) Treatment

ImmunotherapyImmune Checkpoint InhibitorsImmune-related Adverse Event+1 more
Centre Hospitalier Universitaire, Amiens150 enrolled1 locationNCT05813418
Recruiting
Not Applicable

Food Intervention to Reduce Immunotherapy ToXicity

Immune-related Adverse EventDietary Habits
Universitair Ziekenhuis Brussel60 enrolled1 locationNCT05832606
Recruiting

Exploring the Treatment Duration of PD-1 Neoadjuvant Therapy in Stage II-III dMMR Rectal Cancer

Neoadjuvant TherapydMMR Colorectal CancerImmune-related Adverse Event
Xijing Hospital100 enrolled1 locationNCT06613165
Recruiting
Phase 2

SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr)

Mmr DeficiencyImmune-related Adverse EventEndometrial Cancer Stage I+1 more
Queensland Centre for Gynaecological Cancer10 enrolled3 locationsNCT06278857
Recruiting
Not Applicable

The Effect of Serum Ferritin in irAE

Acute LeukemiaMalignant Solid TumorsImmune-related Adverse Event+1 more
Tianjin Medical University Cancer Institute and Hospital1,500 enrolled1 locationNCT06702566
Recruiting

A Single-cell Approach to Identify Biomarkers of Pulmonary Toxicity for Immune Checkpoint Blockade

ImmunotherapyImmune-related Adverse EventsPneumonitis, Interstitial
Universitaire Ziekenhuizen KU Leuven60 enrolled1 locationNCT04807127
Recruiting

Treatment of Immune-related Adverse Events Refractory to Standard Therapy and Associated Changes in Immunophenotype

Immune-related Adverse Event
Lucie Heinzerling50 enrolled1 locationNCT05700565
Recruiting

Fast-Track Cardiovascular Assessment for Suspicion of Cardiovascular Events on Immunecheckpoint Inhibitors

CancerImmune Checkpoint InhibitorCardiovascular Complication+1 more
Institut Mutualiste Montsouris200 enrolled1 locationNCT05799898